Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alpha-5 Integrin
- Ownership
- Private
- Development stage
- Other
01
Overview
Alpha-5 Integrin was a privately held preclinical-stage biotechnology company developing a potentially first-in-class monoclonal antibody targeting alpha-5 integrin for amyotrophic lateral sclerosis and other neuroinflammatory disorders; the program had shown reproducible significant improvements in behavior and survival in the SOD1 mouse model of ALS and had not yet entered clinical trials at the time of its acquisition by Pasithea Therapeutics in June 2022.[1]
- Therapeutic areas
- Neurology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Alpha-5 Integrin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-5 Integrin.